Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Treasury Shares: 2010-2024

Historic Treasury Shares for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $836,562.

  • Anika Therapeutics' Treasury Shares rose 1706.30% to $957,338 in Q2 2025 from the same period last year, while for Jun 2025 it was $957,338, marking a year-over-year increase of 1706.30%. This contributed to the annual value of $836,562 for FY2024, which is 8.45% up from last year.
  • As of FY2024, Anika Therapeutics' Treasury Shares stood at $836,562, which was up 8.45% from $771,358 recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Treasury Shares ranged from a high of $836,562 in FY2024 and a low of $139,000 during FY2020.
  • Moreover, its 3-year median value for Treasury Shares was $771,358 (2023), whereas its average is $761,108.
  • In the last 5 years, Anika Therapeutics' Treasury Shares slumped by 69.25% in 2020 and then spiked by 196.88% in 2021.
  • Anika Therapeutics' Treasury Shares (Yearly) stood at $139,000 in 2020, then surged by 196.88% to $412,658 in 2021, then soared by 63.67% to $675,405 in 2022, then climbed by 14.21% to $771,358 in 2023, then increased by 8.45% to $836,562 in 2024.